PT3456333T - Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica - Google Patents

Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica

Info

Publication number
PT3456333T
PT3456333T PT181966904T PT18196690T PT3456333T PT 3456333 T PT3456333 T PT 3456333T PT 181966904 T PT181966904 T PT 181966904T PT 18196690 T PT18196690 T PT 18196690T PT 3456333 T PT3456333 T PT 3456333T
Authority
PT
Portugal
Prior art keywords
treatment
myelodysplastic syndrome
telomerase inhibitor
imetelstat
inhibitor imetelstat
Prior art date
Application number
PT181966904T
Other languages
English (en)
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,711 external-priority patent/US9375485B2/en
Application filed by Geron Corp filed Critical Geron Corp
Publication of PT3456333T publication Critical patent/PT3456333T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compounds Of Unknown Constitution (AREA)
PT181966904T 2012-12-07 2013-11-15 Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica PT3456333T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07
US201361799069P 2013-03-15 2013-03-15
US13/841,711 US9375485B2 (en) 2012-12-07 2013-03-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P 2013-11-05 2013-11-05

Publications (1)

Publication Number Publication Date
PT3456333T true PT3456333T (pt) 2020-06-01

Family

ID=50883867

Family Applications (2)

Application Number Title Priority Date Filing Date
PT181966904T PT3456333T (pt) 2012-12-07 2013-11-15 Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica
PT138610084T PT2928477T (pt) 2012-12-07 2013-11-15 Utilização do inibidor da telomerase imetelstat para o tratamento de mielofibrose.

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT138610084T PT2928477T (pt) 2012-12-07 2013-11-15 Utilização do inibidor da telomerase imetelstat para o tratamento de mielofibrose.

Country Status (34)

Country Link
EP (3) EP3456333B8 (pt)
JP (5) JP6433911B2 (pt)
KR (3) KR102662590B1 (pt)
CN (2) CN104936602B (pt)
AP (1) AP2015008504A0 (pt)
AU (3) AU2013356533B2 (pt)
BR (1) BR112015013260A2 (pt)
CA (2) CA2892907C (pt)
CL (2) CL2015001530A1 (pt)
CY (2) CY1122169T1 (pt)
DK (3) DK3646876T3 (pt)
EA (1) EA032973B1 (pt)
ES (2) ES2789176T3 (pt)
FI (1) FI3646876T3 (pt)
HK (2) HK1210940A1 (pt)
HR (2) HRP20191784T1 (pt)
HU (2) HUE045098T2 (pt)
IL (2) IL239266B (pt)
LT (3) LT3456333T (pt)
MA (2) MA45504B1 (pt)
ME (1) ME03538B (pt)
MX (3) MX2015007169A (pt)
MY (1) MY180634A (pt)
NZ (1) NZ708920A (pt)
PH (1) PH12015501282A1 (pt)
PL (2) PL2928477T3 (pt)
PT (2) PT3456333T (pt)
RS (2) RS60401B1 (pt)
SG (3) SG10201802926XA (pt)
SI (2) SI3456333T1 (pt)
TN (1) TN2015000249A1 (pt)
UA (2) UA117116C2 (pt)
WO (1) WO2014088785A1 (pt)
ZA (2) ZA201504124B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1778711T (pt) 2004-07-02 2017-10-19 Geron Corp Síntese de monómeros nucleosídeos 3'-amino protegidos
ES2717777T3 (es) * 2013-11-06 2019-06-25 Mayo Found Medical Education & Res Métodos y materiales para tratar neoplasias hematológicas
SI3286203T1 (sl) * 2015-04-23 2020-10-30 Geron Corporation Metode priprave polinukleotida, z uporabo sestavkov multivalentne kationske soli
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
TW201919705A (zh) * 2017-07-28 2019-06-01 美商健生生物科技公司 治療骨髓增生不良症候群之方法
AU2019263064A1 (en) * 2018-04-30 2020-12-03 Kartos Therapeutics, Inc. Methods of treating cancer
WO2021091904A1 (en) * 2019-11-04 2021-05-14 Geron Corporation Use of a janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
WO1998028442A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
JP2007525414A (ja) * 2003-01-31 2007-09-06 ジェシー エル エス オウ スラミン、ペントサン・ポリサルフェート、テロメラーゼアンチセンス、及びテロメラーゼ阻害剤を用いるための方法及び成分
CN1244592C (zh) * 2003-07-11 2006-03-08 暨南大学 抑制白血病细胞端粒酶活性的反义核酸及其应用
EP3682903A1 (en) 2003-09-09 2020-07-22 Geron Corporation Modified oligonucleotides for telomerase inhibition
US20050282893A1 (en) * 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
PT1778711T (pt) 2004-07-02 2017-10-19 Geron Corp Síntese de monómeros nucleosídeos 3'-amino protegidos
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
WO2006113426A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
HUE041448T2 (hu) 2006-10-30 2019-05-28 Geron Corp Kombinált telomerázgátló és gemcitabin rák kezelésére
CN101220044B (zh) * 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
EP3456333B1 (en) 2020-04-01
JP2022179684A (ja) 2022-12-02
CN104936602B (zh) 2020-07-17
CY1123206T1 (el) 2021-10-29
PL2928477T3 (pl) 2020-03-31
IL239266B (en) 2019-11-28
RS59363B1 (sr) 2019-11-29
JP2020041001A (ja) 2020-03-19
CY1122169T1 (el) 2020-11-25
SG10202103341SA (en) 2021-05-28
MA38193B1 (fr) 2018-12-31
AU2013356533A1 (en) 2014-06-12
TN2015000249A1 (en) 2016-10-03
LT3646876T (lt) 2024-05-10
RS60401B1 (sr) 2020-07-31
LT2928477T (lt) 2019-10-10
EP3456333A1 (en) 2019-03-20
CA3188494A1 (en) 2014-06-12
EP3646876B1 (en) 2024-02-14
IL239266A0 (en) 2015-07-30
NZ748134A (en) 2020-10-30
MA38193A1 (fr) 2017-12-29
CN111617252A (zh) 2020-09-04
WO2014088785A8 (en) 2015-07-16
UA126015C2 (uk) 2022-08-03
HRP20191784T1 (hr) 2019-12-27
PL3456333T3 (pl) 2020-09-21
SG10201802926XA (en) 2018-05-30
PH12015501282B1 (en) 2015-08-24
KR102662590B1 (ko) 2024-05-03
JP2016504307A (ja) 2016-02-12
PT2928477T (pt) 2019-10-25
ZA202108991B (en) 2023-05-31
HK1210940A1 (en) 2016-05-13
FI3646876T3 (fi) 2024-05-14
SI2928477T1 (sl) 2019-11-29
KR20150091130A (ko) 2015-08-07
JP2022050537A (ja) 2022-03-30
JP7288098B2 (ja) 2023-06-06
EP2928477A4 (en) 2016-09-21
AU2020267142B2 (en) 2024-05-16
DK3456333T3 (da) 2020-05-18
WO2014088785A1 (en) 2014-06-12
CN104936602A (zh) 2015-09-23
MA45504B1 (fr) 2021-10-29
MA45504A1 (fr) 2020-05-29
MX2020003276A (es) 2020-07-20
EP3456333B8 (en) 2020-05-13
EP2928477B1 (en) 2019-07-24
NZ708920A (en) 2020-08-28
HRP20200993T1 (hr) 2020-11-27
HUE045098T2 (hu) 2019-12-30
ZA201504124B (en) 2017-05-31
JP6433911B2 (ja) 2018-12-05
MX2022015437A (es) 2023-01-11
ES2744790T3 (es) 2020-02-26
IL280144A (en) 2021-03-01
DK2928477T3 (da) 2019-10-07
HUE049858T2 (hu) 2020-11-30
CA2892907C (en) 2023-03-21
AU2020267142A1 (en) 2020-12-03
HK1212226A1 (en) 2016-06-10
EP2928477A1 (en) 2015-10-14
DK3646876T3 (da) 2024-05-06
EP3646876A1 (en) 2020-05-06
UA117116C2 (uk) 2018-06-25
EA201590878A1 (ru) 2016-04-29
SG11201504383TA (en) 2015-07-30
JP2018035196A (ja) 2018-03-08
ME03538B (me) 2020-07-20
LT3456333T (lt) 2020-06-25
CL2015001530A1 (es) 2016-03-28
KR20210107906A (ko) 2021-09-01
BR112015013260A2 (pt) 2018-02-06
JP6998191B2 (ja) 2022-02-04
CA2892907A1 (en) 2014-06-12
PH12015501282A1 (en) 2015-08-24
KR20230028590A (ko) 2023-02-28
MX2015007169A (es) 2016-03-31
AU2018282364A1 (en) 2019-05-23
CL2017002156A1 (es) 2018-05-04
SI3456333T1 (sl) 2020-10-30
KR102294819B1 (ko) 2021-09-01
AU2013356533B2 (en) 2018-09-27
AP2015008504A0 (en) 2015-06-30
MY180634A (en) 2020-12-03
ES2789176T3 (es) 2020-10-26
EA032973B1 (ru) 2019-08-30

Similar Documents

Publication Publication Date Title
HRP20181679T1 (hr) Amidni spojevi za liječenje hiv
IL243976A0 (en) kdm1a inhibitors for disease treatment
HK1210957A1 (en) Effluz inhibitor compositions and methods of treatment using the same
EP3019491A4 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
SG11201501173SA (en) PI3Kδ INHIBITOR
HK1207583A1 (en) Use of biotin for the treatment of multiple sclerosis
EP2921510A4 (en) SURFACE TREATMENT COMPOSITION
EP3015480A4 (en) Surface treatment agent
SI3456333T1 (sl) Uporaba telomeraznega inhibitorja imetelstat za zdravljenje mielodisplastičnega sindroma
EP2968204A4 (en) TREATMENT WITH A PHOSPHODIESTERASE HEMMER
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
AU354694S (en) Surface treatment pad
HK1205754A1 (en) Agent for the surface epilamization of an article
EP2812190A4 (en) SURFACE TREATMENT COMPOSITION
HK1210421A1 (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3-
GB201314623D0 (en) Novel mucinase for use in therapy or prophylaxis